CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-18 | Kulkarni Samarth Chief Executive Officer | Option exercise · Restricted Stock Units | −13,250 | 26,500 | ||
| 2024-02-15 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +20,000 | $19.12 | $382K | 207,377 |
| 2024-02-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −12,949 | $79.94 | $1.0M | 194,428 |
| 2024-02-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −5,951 | $81.04 | $482K | 188,477 |
| 2024-02-15 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −1,100 | $81.66 | $90K | 187,377 |
| 2024-02-15 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 39,582 | ||
| 2024-01-29 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +50,000 | $19.12 | $956K | 237,377 |
| 2024-01-29 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −49,300 | $60.50 | $3.0M | 188,077 |
| 2024-01-29 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −700 | $61.10 | $43K | 187,377 |
| 2024-01-29 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −50,000 | 100,000 | ||
| 2024-01-16 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +20,000 | $19.12 | $382K | 207,377 |
| 2024-01-16 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −20,000 | $62.50 | $1.3M | 187,377 |
| 2024-01-16 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 59,582 | ||
| 2023-10-13 | Prasad Raju Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +13,832 | 13,832 | ||
| 2023-10-13 | Morrow Phuong Khanh Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +16,667 | 16,667 | ||
| 2023-10-13 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +52,500 | 52,500 | ||
| 2023-10-13 | Kulkarni Samarth Chief Executive Officer | Grant or award · Restricted Stock Unit | +25,000 | 25,000 | ||
| 2023-10-13 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +16,667 | 16,667 | ||
| 2023-10-13 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Restricted Stock Units | +6,340 | 6,340 | ||
| 2023-06-08 | George Simeon Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 |
Page 15 of 46 · 910 trades